title: Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome.
authors.forename: J S
authors.initials: JS
authors.lastname: Lopez
authors.forename: M D
authors.initials: MD
authors.lastname: de Smet
authors.forename: H
authors.initials: H
authors.lastname: Masur
authors.forename: B U
authors.initials: BU
authors.lastname: Mueller
authors.forename: P A
authors.initials: PA
authors.lastname: Pizzo
authors.forename: R B
authors.initials: RB
authors.lastname: Nussenblatt
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D015822:Eye Infections, Parasitic / Q000150:complications / Q000188:drug therapy; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D014126:Toxoplasmosis, Ocular / Q000150:complications / Q000188:drug therapy*
chemical_list: D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D053626:Atovaquone